Cargando…
Tardive dyskinesia with low dose amisulpride
In recent years, there has been an increasing trend to use amisulpride in the treatment of dysthymia and also as an adjunct treatment in patients with major depression. At low doses (50 mg), amisulpride preferentially blocks presynaptic auto receptors, enhances dopamine release, and therefore acts a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574463/ https://www.ncbi.nlm.nih.gov/pubmed/23440033 http://dx.doi.org/10.4103/0019-5545.105523 |
_version_ | 1782259588065656832 |
---|---|
author | Tharoor, Hema Padmavati, R. |
author_facet | Tharoor, Hema Padmavati, R. |
author_sort | Tharoor, Hema |
collection | PubMed |
description | In recent years, there has been an increasing trend to use amisulpride in the treatment of dysthymia and also as an adjunct treatment in patients with major depression. At low doses (50 mg), amisulpride preferentially blocks presynaptic auto receptors, enhances dopamine release, and therefore acts as a dopaminergic compound able to resolve the dopaminergic hypo activity that characterizes depression. Based on experimental data, amisulpride is the drug of choice for dopaminergic transmission disorders, both in depression and in schizophrenia. This case highlights the development of dyskinesia in a depressed patient treated with low dose amisulpride and fluvoxamine. |
format | Online Article Text |
id | pubmed-3574463 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-35744632013-02-22 Tardive dyskinesia with low dose amisulpride Tharoor, Hema Padmavati, R. Indian J Psychiatry Case Report In recent years, there has been an increasing trend to use amisulpride in the treatment of dysthymia and also as an adjunct treatment in patients with major depression. At low doses (50 mg), amisulpride preferentially blocks presynaptic auto receptors, enhances dopamine release, and therefore acts as a dopaminergic compound able to resolve the dopaminergic hypo activity that characterizes depression. Based on experimental data, amisulpride is the drug of choice for dopaminergic transmission disorders, both in depression and in schizophrenia. This case highlights the development of dyskinesia in a depressed patient treated with low dose amisulpride and fluvoxamine. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3574463/ /pubmed/23440033 http://dx.doi.org/10.4103/0019-5545.105523 Text en Copyright: © Indian Journal of Psychiatry http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Tharoor, Hema Padmavati, R. Tardive dyskinesia with low dose amisulpride |
title | Tardive dyskinesia with low dose amisulpride |
title_full | Tardive dyskinesia with low dose amisulpride |
title_fullStr | Tardive dyskinesia with low dose amisulpride |
title_full_unstemmed | Tardive dyskinesia with low dose amisulpride |
title_short | Tardive dyskinesia with low dose amisulpride |
title_sort | tardive dyskinesia with low dose amisulpride |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574463/ https://www.ncbi.nlm.nih.gov/pubmed/23440033 http://dx.doi.org/10.4103/0019-5545.105523 |
work_keys_str_mv | AT tharoorhema tardivedyskinesiawithlowdoseamisulpride AT padmavatir tardivedyskinesiawithlowdoseamisulpride |